<p>JonesTrading 分析师 Soumit Roy 重申了对 CGON 股票的看涨态度，昨日给予买入评级。</p>
<h3>TipRanks 网络星期一促销</h3>
<ul>
<li>享受 TipRanks Premium 60% 的折扣，获取数据支持的洞察和研究工具，让您自信投资。</li>
<li>订阅 TipRanks 的智能投资者精选，通过我们高表现的模型投资组合查看我们的数据 - 现在也享受 60% 的折扣。</li>
</ul>
<p>Soumit Roy 给予买入评级是基于 CG Oncology 在其膀胱癌治疗方面的有希望的数据。该公司的溶瘤免疫疗法 cretostimogene 在治疗高等级非肌肉侵袭性膀胱癌（NMIBC）方面显示出令人印象深刻的结果，特别是在 BCG-Naive 和 BCG-Unresponsive 的情况下。当给药方案缩短时，该治疗显示出更高的完全应答率，优于竞争对手和标准护理选项。</p>
<p>此外，cretostimogene 在具有挑战性的患者群体中显示出更优的无事件生存率，增强了其在各种 NMIBC 情境下的疗效。积极的数据结果解决了之前关于该药物在特定情境外表现及其安全性的问题。随着正在进行的试验和未来数据结果的预期，市场对 cretostimogene 扩大应用潜力和进一步巩固市场地位的乐观情绪，使得买入评级得以合理化。</p>

CGON

<p>JonesTrading 分析师 Soumit Roy 重申了对 CG Oncology 股票的买入评级，原因是其膀胱癌治疗药物 cretostimogene 的数据表现令人鼓舞。该治疗在高等级非肌肉侵袭性膀胱癌中显示出令人印象深刻的效果，超越了竞争对手和标准护理选项。积极的数据结果解决了之前的担忧，正在进行的试验预计将进一步巩固其市场地位</p>

<p>JonesTrading analyst Soumit Roy has reiterated their bullish stance on CGON stock, giving a Buy rating yesterday.</p>
<div class="lb-trans"><p>JonesTrading 分析师 Soumit Roy 重申了对 CGON 股票的看涨态度，昨日给予买入评级。</p>
</div><h3>TipRanks Cyber Monday Sale</h3>
<div class="lb-trans"><h3>TipRanks 网络星期一促销</h3>
</div><ul>
<li>Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.</li>
<li>Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio -  now also 60% off</li>
</ul>
<div class="lb-trans"><ul>
<li>享受 TipRanks Premium 60% 的折扣，获取数据支持的洞察和研究工具，让您自信投资。</li>
<li>订阅 TipRanks 的智能投资者精选，通过我们高表现的模型投资组合查看我们的数据 - 现在也享受 60% 的折扣。</li>
</ul>
</div><p>Soumit Roy has given his Buy rating due to a combination of factors surrounding CG Oncology’s promising data on their bladder cancer treatment. The company’s oncolytic immunotherapy, cretostimogene, has shown impressive results in treating high-grade non-muscle invasive bladder cancer (NMIBC), particularly in the BCG-Naive and BCG-Unresponsive settings. The treatment demonstrated a higher complete response rate when the administration protocol was shortened, outperforming competitors and standard care options.</p>
<div class="lb-trans"><p>Soumit Roy 给予买入评级是基于 CG Oncology 在其膀胱癌治疗方面的有希望的数据。该公司的溶瘤免疫疗法 cretostimogene 在治疗高等级非肌肉侵袭性膀胱癌（NMIBC）方面显示出令人印象深刻的结果，特别是在 BCG-Naive 和 BCG-Unresponsive 的情况下。当给药方案缩短时，该治疗显示出更高的完全应答率，优于竞争对手和标准护理选项。</p>
</div><p>Moreover, cretostimogene has shown superior event-free survival in challenging patient groups, reinforcing its efficacy across various NMIBC settings. The positive data readouts have addressed previous concerns about the drug’s performance outside specific settings and its safety profile. With ongoing trials and future data readouts expected, there is optimism about cretostimogene’s potential to expand its application and further solidify its market position, justifying the Buy rating.</p>
<div class="lb-trans"><p>此外，cretostimogene 在具有挑战性的患者群体中显示出更优的无事件生存率，增强了其在各种 NMIBC 情境下的疗效。积极的数据结果解决了之前关于该药物在特定情境外表现及其安全性的问题。随着正在进行的试验和未来数据结果的预期，市场对 cretostimogene 扩大应用潜力和进一步巩固市场地位的乐观情绪，使得买入评级得以合理化。</p>
</div>

CG oncology 的 Cretostimogene 的积极数据证明了给予买入评级的合理性